495 Firms Bid on 859 Products in China's 12th National Drug Procurement Round
On July 31st, at 10:30 AM, the bidding process for the 12th batch of nationally organized centralized drug procurement concluded with 495 companies submitting bids for 859 products. The next stage involves the announcement of the bids. This initiative by China's medical insurance authorities has previously conducted 11 successful rounds of centralized drug procurement. These earlier rounds have collectively secured bids for 490 different types of drugs. In total, over 800 companies had more than 2,500 products selected in these previous procurement rounds. The goal of these national centralized procurement efforts is to make high-quality, affordable medications widely available across commonly used clinical treatment areas.
The 12th round of China's national centralized drug procurement continues the established policy of leveraging bulk purchasing power to drive down pharmaceutical costs and expand access to essential medicines. This systematic approach aims to create a more efficient healthcare market by incentivizing manufacturers to compete on price and quality for large-volume contracts. The program's scale, evidenced by the increasing number of participating firms and products, suggests a maturing market mechanism. Future considerations may involve the long-term impact on pharmaceutical innovation, the sustainability of pricing strategies, and the potential for global supply chain integration within such large-scale domestic procurement frameworks.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.